<DOC>
	<DOCNO>NCT01743625</DOCNO>
	<brief_summary>The purpose study show effectiveness COV155 compare placebo subject acute moderate severe pain follow bunionectomy surgery .</brief_summary>
	<brief_title>Safety Efficacy Study COV155 Post-operative Bunionectomy Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<criteria>Inclusion Criteria Voluntarily provide write informed consent General good health 18 75 year age Scheduled primary unilateral first metatarsal bunionectomy ( collateral procedure ) Body mass index ≤33 Female subject eligible Not pregnant lactating ; plan become pregnant duration study ; Surgically sterile , monogamous partner surgically sterile , least 2 year postmenopausal , practice acceptable birth control 2 month prior Screening , study 1 week follow last dose COV155 Male subject must sterile ( biologically surgically ) use reliable birth control study least 1 week last dose COV155 Classified either Physical Status1 ( PS ) PS2 American Society Anesthetists ( ASA ) Physical Status Classification System . Willing complete pain assessment clinic visit . Additional inclusion criterion randomization DoubleBlind Phase : Subjects must experience postoperative pain intensity score ≥5 0 10 Numerical Pain Rating Score ( NPRS ) 1 hour , le 9 hour discontinue nerve block , least 30 minute last ice pack remove ( use ) . Exclusion Criteria Uncontrolled medical condition , serious intercurrent illness , clinically significant general health condition , extenuate circumstance may significantly decrease study compliance otherwise preclude study participation Clinically significant abnormal ECG Screening Gastric bypass surgery gastric band Previous abdominal surgery within past year history abdominal adhesion , know suspect paralytic ileus History medical condition would alter absorption , distribution , metabolism excretion COV155 include limit severe chronic diarrhea , chronic constipation , severe irritable bowel syndrome , unexplained weight loss History severe bronchial asthma , hypercarbia , hypoxia sleep apnea Certain lab abnormality Addison 's disease , benign prostatic hyperplasia , kidney disease Donated blood blood component within 3 month prior Screening study Known allergy/hypersensitivity opioid analgesic , anesthetic , acetaminophen , non steroidal antiinflammatory drug ( NSAIDs ) History intolerance short term opioid use Unable discontinue use prohibit medication history substance alcohol abuse within 2 year prior Screening positive quantitative urine drug test Screening Positive human immunodeficiency virus , hepatitis B C Dysphagia and/or swallow study treatment whole History migraine frequent headache within previous 2 year , seizure , currently take anticonvulsant Previously receive COV155 clinical study , undergone bunionectomy within last 3 month Received investigational drug device within 4 week prior Screening study Active malignancy history malignancy within 2 year prior Screening , completely eradicated cervical squamous cell carcinoma situ basal skin cancer Currently take neuroleptic stable dos benzodiazepine Other criterion specify protocol Additional exclusion criterion randomization DoubleBlind Phase : Have surgical complication could compromise safety subject confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>